Zobrazeno 1 - 10
of 341
pro vyhledávání: '"Begoña, Bermejo"'
Autor:
Sandra Torres-Ruiz, Iris Garrido-Cano, Ana Lameirinhas, Octavio Burgués, Cristina Hernando, María Teresa Martínez, Federico Rojo, Begoña Bermejo, Marta Tapia, Juan Antonio Carbonell-Asins, Carlos Javier Peña, Ana Lluch, Juan Miguel Cejalvo, Eduardo Tormo, Pilar Eroles
Publikováno v:
Cell Death Discovery, Vol 10, Iss 1, Pp 1-13 (2024)
Abstract Despite progress in breast cancer treatment, a significant portion of patients still relapse because of drug resistance. The involvement of microRNAs in cancer progression and chemotherapy response is well established. Therefore, this study
Externí odkaz:
https://doaj.org/article/3a1b2fe95e2d47d181a620741b4f85f7
Autor:
José Enrique Alés-Martínez, Judith Balmaña, Pedro Sánchez-Rovira, Francisco Javier Salvador Bofill, Jose Ángel García Sáenz, Isabel Pimentel, Serafín Morales, María Fernández-Abad, Ainhara Lahuerta Martínez, Neus Ferrer, Pilar Zamora, Begoña Bermejo, Tamara Díaz-Redondo, María Helena López-Ceballos, María Galán, Jhudit Pérez-Escuredo, Laura Calabuig, Miguel Sampayo, José Manuel Pérez-Garcia, Javier Cortés, Antonio Llombart-Cussac
Publikováno v:
Breast, Vol 77, Iss , Pp 103780- (2024)
Purpose: To evaluate the efficacy and safety of the combination of olaparib plus trastuzumab in patients with HER2-positive advanced breast cancer (ABC) and germinal BRCA mutations (gBRCAm). Methods: OPHELIA (NCT03931551) was a single-arm, open-label
Externí odkaz:
https://doaj.org/article/19f49dc9a9694e038d227468d5e24fe9
Autor:
Virginia Lope, Ángel Guerrero-Zotano, Nerea Fernández de Larrea-Baz, Silvia Antolín, Marta Benavent Viñuales, Begoña Bermejo, Emma Ruiz-Moreno, José Manuel Baena-Cañada, Lorena París, Antonio Antón, José Ignacio Chacón, Montserrat Muñoz, José Angel García-Sáenz, Clara Olier, Pedro Sánchez Rovira, Angels Arcusa Lanza, Sonia González, Joan Brunet, Amparo Oltra, Susana Bezares, Libertad Rosell, Beatriz Pérez-Gómez, Roberto Pastor-Barriuso, Miguel Martín, Marina Pollán
Publikováno v:
The Journal of Nutrition, Health and Aging, Vol 28, Iss 8, Pp 100312- (2024)
Objectives: Adherence to healthy lifestyle recommendations has been reported to improve health-related quality of life (HRQL) in breast cancer (BC) patients, but the influence of long-term behavioral changes remains unknown. We evaluated the associat
Externí odkaz:
https://doaj.org/article/e8107c1dad0a4eca96faa38a23e42f5e
Autor:
Antonio Llombart-Cussac, José Manuel Pérez-Garcia, Manuel Ruiz Borrego, Pablo Tolosa, Salvador Blanch, Adela Fernández-Ortega, Ander Urruticoechea, Isabel Blancas, Cristina Saura, Beatriz Rojas, Begoña Bermejo, José Ponce Lorenzo, María Gion, Patricia Cortez-Castedo, Elisenda Llabres, Elena Galve, Juan Fernando Cueva, Ana López, José Luis Alonso-Romero, Santiago González-Santiago, Eduardo Martínez de Dueñas, Eva Ciruelos, Griselda Martrat, Petra Gener, Daniel Alcalá-López, Miguel Sampayo-Cordero, Fernando Gómez-Peralta, Javier Cortés
Publikováno v:
EClinicalMedicine, Vol 71, Iss , Pp 102520- (2024)
Summary: Background: Hyperglycaemia is an early and frequent adverse event during alpelisib treatment. METALLICA aimed to evaluate prophylactic metformin to prevent or reduce hyperglycaemia occurrence in patients with HR+/HER2−/PIK3CA-mutated advan
Externí odkaz:
https://doaj.org/article/c5ba8bd9a6864624b463e00529accd71
Autor:
Sara Santana-Hernández, Jesús Suarez-Olmos, Sonia Servitja, Pau Berenguer-Molins, Marcel Costa-Garcia, Laura Comerma, Anna Rea, Julia Perera-Bel, Silvia Menendez, Oriol Arpí, Begoña Bermejo, María Teresa Martínez, Juan Miguel Cejalvo, Iñaki Comino-Méndez, Javier Pascual, Emilio Alba, Miguel López-Botet, Federico Rojo, Ana Rovira, Joan Albanell, Aura Muntasell
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-15 (2024)
Abstract Background The variability in responses to neoadjuvant treatment with anti-HER2 antibodies prompts to personalized clinical management and the development of innovative treatment strategies. Tumor-infiltrating Natural Killer (TI-NK) cells ca
Externí odkaz:
https://doaj.org/article/5bc22c2f73dc42618cc14ecab70aa357
Autor:
Iris Garrido‐Cano, Anna Adam‐Artigues, Ana Lameirinhas, Juan F. Blandez, Vicente Candela‐Noguera, Federico Rojo, Sandra Zazo, Juan Madoz‐Gúrpide, Ana Lluch, Begoña Bermejo, Felix Sancenón, Juan Miguel Cejalvo, Ramón Martínez‐Máñez, Pilar Eroles
Publikováno v:
Cancer Communications, Vol 42, Iss 12, Pp 1412-1416 (2022)
Externí odkaz:
https://doaj.org/article/7c968fc3805d4bed95fdb0851caa2240
Autor:
Tiziana Triulzi, Giampaolo Bianchini, Serena Di Cosimo, Tadeusz Pienkowski, Young‐Hyuck Im, Giulia Valeria Bianchi, Barbara Galbardi, Matteo Dugo, Loris De Cecco, Ling‐Ming Tseng, Mei‐Ching Liu, Begoña Bermejo, Vladimir Semiglazov, Giulia Viale, Juan de laHaba‐Rodriguez, Do‐Youn Oh, Brigitte Poirier, Pinuccia Valagussa, Luca Gianni, Elda Tagliabue
Publikováno v:
Molecular Oncology, Vol 16, Iss 12, Pp 2355-2366 (2022)
As most erb‐b2 receptor tyrosine kinase 2 (HER2)‐positive breast cancer (BC) patients currently receive dual HER2‐targeting added to neoadjuvant chemotherapy, improved methods for identifying individual response, and assisting postsurgical salv
Externí odkaz:
https://doaj.org/article/04d4128992ee4c3590607960b247f2b8
Autor:
Tomás Pascual, Mafalda Oliveira, Patricia Villagrasa, Vanesa Ortega, Laia Paré, Begoña Bermejo, Serafín Morales, Kepa Amillano, Rafael López, Patricia Galván, Jordi Canes, Fernando Salvador, Paolo Nuciforo, Isabel T. Rubio, Antonio Llombart-Cussac, Serena Di Cosimo, José Baselga, Nadia Harbeck, Aleix Prat, Javier Cortés
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-11 (2021)
Abstract Eribulin prolongs overall survival in patients with pre-treated advanced breast cancer. However, no biomarker exists to prospectively select patients who will benefit the most from this drug. SOLTI-1007-NeoEribulin is a phase II, open-label,
Externí odkaz:
https://doaj.org/article/41c7b00b4fff4204abca055bdf4c6649
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Sandra Torres-Ruiz, Eduardo Tormo, Iris Garrido-Cano, Ana Lameirinhas, Federico Rojo, Juan Madoz-Gúrpide, Octavio Burgués, Cristina Hernando, Begoña Bermejo, María Teresa Martínez, Ana Lluch, Juan Miguel Cejalvo, Pilar Eroles
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 4, p 3601 (2023)
Due to the lack of specific targets, cytotoxic chemotherapy still represents the common standard treatment for triple-negative breast patients. Despite the harmful effect of chemotherapy on tumor cells, there is evidence that treatment could modulate
Externí odkaz:
https://doaj.org/article/58fb6b02a97b494abfaa2932b5aa3d4a